Metagenomi Therapeutics (MGX) Income from Continuing Operations (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Income from Continuing Operations of 23059000.0 for Q1 2026, up 7.91% year-over-year from 21369195.79 in Q1 2025, and down 459.41% quarter-over-quarter from 4122000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Income from Continuing Operations for 4 consecutive years, with 23059000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 7.91% year-over-year to 23059000.0; the TTM figure through Mar 2026 stood at 67482000.0 (up 13.43% YoY), while the FY2025 annual figure was 69462000.0, up 11.01% from the prior year.
- Income from Continuing Operations fell to 23059000.0 in Q1 2026 per MGX's latest filing, from 4122000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4122000.0 in Q4 2025 and bottomed at 25148000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 18033846.15 across 4 years, with a median of 19820000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 114.23% — and 2025, when it jumped 82.38%.
- Metagenomi Therapeutics' Income from Continuing Operations stood at 19294000.0 in 2023, then fell by 21.27% to 23398000.0 in 2024, then surged by 82.38% to 4122000.0 in 2025, then tumbled by 459.41% to 23059000.0 in 2026.
- Business Quant data shows MGX's Income from Continuing Operations at 23059000.0 in Q1 2026, 4122000.0 in Q4 2025, and 20393000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | -27.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.48 Mn |
| Mar 31, 2026 | -23.06 Mn |
| Dec 31, 2025 | -4.12 Mn |
| Sep 30, 2025 | -20.39 Mn |
| Jun 30, 2025 | -19.91 Mn |
| Mar 31, 2025 | -25.04 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Sep 30, 2024 | -18.77 Mn |
| Jun 30, 2024 | -10.74 Mn |
| Mar 31, 2024 | -25.15 Mn |
| Dec 31, 2023 | -19.29 Mn |
| Sep 30, 2023 | -19.82 Mn |
| Jun 30, 2023 | -13.01 Mn |
| Mar 31, 2023 | -11.74 Mn |